Navigation Links
European researchers harness unique properties of boron to develop new drugs and diagnostics
Date:10/21/2008

Researchers are on the verge of unleashing the power of the element boron in a new generation of drugs and therapies, as decades of research begins to bear fruit. Boron has to date far been one of biology's best kept secrets, but is now attracting fast growing research interest and investment from the pharmaceutical industry in the quest for novel drugs to tackle cancer and infectious diseases, potentially overcoming limitations and side effects of current products.

Europe's response to the challenges and opportunities of boron chemistry in medicine was discussed at a recent workshop, Biobor Exploring New Opportunities Of Boron Chemistry Towards Medicine. According to its convenor Zbigniew Lesnikowski, the ESF workshop set the stage for a new era of boron therapies going beyond the current application in cancer radiotherapy via boron neutron capture therapy (BNCT), in which the element is used to help translate beams of neutrons into radiation that targets tumour cells with less "collateral damage" of surrounding healthy tissue.

"Yes, it became obvious during the workshop that there is now sufficient knowledge and enough compounds to support a broad program of screening in the quest for new antiviral and anticancer drugs containing essential boron components," said Lesnikowski. There was also scope for improving the application of BNCT to cancer, but besides these two therapeutic avenues, boron also has vast potential as the basis for compounds in diagnosis and biosensing, and also for novel bioorganic materials, said Lesnikowski.

The applications in bio sensing, biomaterials, and drug development all spring from the fundamental chemical properties of boron. All life is derived ultimately from the element carbon, which lies next to boron in the periodic table of elements, their respective atomic numbers being six and five. Boron compounds share some similarities with carbon but also have important differences. It is the combinatio
'/>"/>

Contact: Zbigniew Lesnikowski
zlesnikowski@cbm.pan.pl
48-422-723-629
European Science Foundation
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Last chance for media to register for ECCO 14 -- the European Cancer Conference
2. 2 French scientists win European award for communication
3. Three-way mating game of North American lizard found in distant European relative
4. European lead in reading past climates from ice cores
5. Hot spots the key to controlling European carp in Australia
6. IdentiPHI Opens Paris Office to Boost European Sales and Support
7. European Union forests expanding, absorbing carbon at surprisingly high rate: study
8. First European Lung Cancer Conference
9. ESFs European ice core project EPICA receives prestigious Descartes Prize
10. European membrane expertise to focus on new treatments for human diseases
11. European light research opens door for optical storage and computing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , Jan. 13, 2015  Today, FreeWavz ( ... launched its crowdfunding campaign on Fundable, https://www.fundable.com/freewavz ... build of production capacity to meet customer demand. ... Photo - http://photos.prnewswire.com/prnh/20150113/168790 ...
(Date:1/22/2015)... Jan. 20, 2015 NXT-ID, Inc. (NASDAQ: NXTD and ... reports on the recent success of the Wocket™ smart wallet at CES ... smart wallet was named as one of the "11 Hot Products at ... Products Launched At CES So Far" by Newseveryday.com and "The top 10 ...
(Date:1/22/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/wxdglm/global_wearable ... "Global Wearable Technologies Market and Applications, Opportunities, Industry ... Forecast 2014-2020" report to their offering. ... that can be worn on the user,s body ...
Breaking Biology News(10 mins):FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2
... a small shark species, there seems to be super-sized confusion ... of New Hampshire, one thing is clear definite changes ... two decades. Commercial fishermen haul up nets ... yellow-eyed creatures are often considered a nuisance. However, fishery management ...
... at the University of Vermont Cardiovascular Research Institute, ... the heart of plasminogen activator inhibitor type-1 (PAI-1) ... the March 2009 issue of Experimental Biology ... accompany insulin resistance and type 2 diabetes, as ...
... 24, 2009) − When participants performed a mentally fatiguing task ... quickly than when they did the same exercise when mentally ... that mental fatigue did not cause the heart or muscles ... we reach exhaustion. The researchers said the next step is ...
Cached Biology News:UNH researchers studying spiny dogfish, Gulf of Maine's mini shark 2UNH researchers studying spiny dogfish, Gulf of Maine's mini shark 3Plasminogen activator inhibitor type-1 -- a potential link between heart failure and diabetes 2Mental fatigue can affect physical endurance 2Mental fatigue can affect physical endurance 3
(Date:2/27/2015)... Nova Scotia (PRWEB) February 27, 2015 ... been made aware of a fraudulent press release disseminated ... purporting to be from Immunovaccine. This press release states ... Gilead Science, Inc. The press release did not ... the information contained within the press release. Please ...
(Date:2/27/2015)... 27, 2015 Research and Markets ( http://www.researchandmarkets.com/research/p2ddnr/global_market ... Report of Trypsin" report to their offering. , ... at providing comprehensive data on Trypsin globally and regionally ( ... North America , Latin America ... to Trypsin This report focuses on three primary ...
(Date:2/27/2015)... SAN DIEGO , Feb. 27, 2015  Pfenex ... in the development of biosimilar therapeutics, today announced that ... San Francisco Marriott Marquis on March 2 nd ... will participate on a panel discussing the current state ... World of Biosimilars . For more ...
(Date:2/27/2015)... --  PureTech , a science and technology R&D company ... technologies in the healthcare sector, announced today the appointment ... of the Board of Directors of Sanofi, to its ... a pleasure to know Chris for many years and ... together more closely now," said Dr. Robert Langer ...
Breaking Biology Technology:Immunovaccine Disclaims Hoax Press Release 2Global Market Report of Trypsin 2014-2018 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 4
... Coulter, Inc. (NYSE: BEC ), a leading ... and innovate complex biomedical testing, today announced that it ... stock, the proceeds of which it expects to use ... the diagnostic systems portion of Olympus Corporation,s Life Science ...
... Technologies, Inc. (OTC Bulletin Board: MCLN) announced today that ... of the Company,s existing Common Stock Purchase Warrants with ... 29, 2008 ("Existing Warrants") for newly issued Common Stock ... for a lesser number shares of our common stock, ...
... 19 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ... its corporate partner, Boston Scientific Corporation (NYSE: ... TAXUS(R) Element(TM) Paclitaxel-Eluting Coronary Stent System in select ... new platinum chromium alloy engineered specifically for coronary ...
Cached Biology Technology:Beckman Coulter, Inc. Announces Pricing of Common Stock Offering 2Beckman Coulter, Inc. Announces Pricing of Common Stock Offering 3MedClean Technologies, Inc. Announces Private Offer to Exchange Warrants 2MedClean Technologies, Inc. Announces Private Offer to Exchange Warrants 3MedClean Technologies, Inc. Announces Private Offer to Exchange Warrants 4Angiotech's corporate partner, Boston Scientific, announces launch of third-generation TAXUS(R) Element(TM) Stent 2Angiotech's corporate partner, Boston Scientific, announces launch of third-generation TAXUS(R) Element(TM) Stent 3Angiotech's corporate partner, Boston Scientific, announces launch of third-generation TAXUS(R) Element(TM) Stent 4Angiotech's corporate partner, Boston Scientific, announces launch of third-generation TAXUS(R) Element(TM) Stent 5
PPOX Immunogen: PPOX (AAH02357, 378 a.a. ~ 478 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
KRIT1 Immunogen: KRIT1 (NP_004903, 637 a.a. ~ 737 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Rabbit polyclonal to MAP3K12 ( Abpromise for all tested applications). Antigen: Synthetic peptide conjugated to KLH from the C-terminal region of human MAP3K12 Entrez Gene ID: 7786 Swiss ...
Anti-MMP-25 (Membrane-type MMP-6, Mt6MMP), hinge region; rabbit host...
Biology Products: